

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復旦張江生物醫藥股份有限公司
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code:1349)

VOLUNTARY ANNOUNCEMENT
THE PROGRESS OF PROPOSED ISSUE OF A SHARES

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the “**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company dated 20 March 2020, in relation to, among other things, the notice from the Shanghai Stock Exchange (the “**Shanghai Stock Exchange**”) informing the Company that the initial public offering of A Shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange by the Company (the “**Proposed Issue of A Shares**”) will be reviewed in the review meeting (the “**Review Meeting**”) of the Listing Committee of the Sci-tech Innovation Board (the “**Listing Committee**”) to be held on 31 March 2020. Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcement.

The Company received a supplementary notice from the Shanghai Stock Exchange today. According to the relevant novel coronavirus pneumonia epidemic prevention and control regulations and an emergency notice of a relevant member of the Listing Committee, the member is unable to arrive at the designated video conference place at the time of the original Review Meeting. In accordance with the relevant provisions of the Shanghai Stock Exchange, the Review Meeting is postponed and will be rescheduled in the near future.

Further announcement(s) regarding the progress of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement is for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board
Wang Hai Bo
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)
Mr. Su Yong (Executive Director)
Mr. Zhao Da Jun (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Zhou Zhong Hui (Independent Non-executive Director)
Mr. Lam Yiu Kin (Independent Non-executive Director)
Mr. Xu Qing (Independent Non-executive Director)
Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

25 March 2020

** For identification purpose only*